Hybrid biological matrix and its preparation method

CN122555580APending Publication Date: 2026-08-11MNT LLC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-11
Publication Date
2026-08-11

AI Technical Summary

Technical Problem

[0005]上述公开的技术方案的缺点在于生物移植物表面的生物相容性低，这是由于在预处理步骤中使用了有毒洗涤剂SDS，以及由于复杂涂层的多步制备导致基质制备过程复杂

Benefits of technology

[0058] The claimed invention allows for the creation of a “smart” protective barrier formed through a single-stage coating of composite chitosan nanoparticles (impregnated with silver or vancomycin nanoparticles) under pressure from a CO2-saturated detergent solution in a carbonated solution. No information exists in the scientific and technical literature regarding such methods for treating biological grafts. The claimed invention induces donor cell death and removes immunogenic and calcifying lipid components from the tissue, preventing calcification in the recipient, improving the biocompatibility of such grafts, and allowing for the creation of a nanoparticle protective coating that releases an antimicrobial agent during infection development. By selecting the preparation conditions of the composite chitosan nanoparticles and coating them under pressure from a carbonated solution onto a purified biological matrix, a stable nanoparticle coating encapsulated with an antimicrobial agent can be formed. Therefore, the claimed method for preparing the biological matrix differs from its closest analogue in that it effectively pre-decellularizes the original biological tissue using a biocompatible method with significantly less toxic detergents (completely free of SDS) and creates a protective barrier from a coating of composite chitosan nanoparticles based on an encapsulating antimicrobial agent using a relatively simple, single-stage method.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention relates to the fields of biotechnology, medicine, and cosmetology, specifically to a hybrid matrix for use as a biological graft in the manufacture of cardiac prostheses. The technical effect of this invention is to improve the surface biocompatibility, stability, and durability of biological grafts that provide antimicrobial responses, and to prevent calcification. The preparation method of the hybrid biological matrix includes the following steps: a two-stage preliminary purification of the biological matrix substrate for 0.75-6 hours, including decellularization of xenogeneic pericardium in a CO2-saturated 2-5 wt% Tween 80 aqueous-alcohol solution at a temperature of 20-40°C and a pressure of 10-30 MPa; subsequently, at a temperature of 20-40°C and a pressure of 10-30 MPa, using a solution containing saturated CO2 and 1-1.5 vol% of a 2-5 wt% Tween 80 aqueous-alcohol solution. A multi-component system of liquid additives was used to decellularize xenogeneic pericardium; the bio-matrix substrate was stabilized for 3-4 hours using a 0.1-0.5 wt% genipin aqueous buffer solution with a pH of 6.0-7.4; and a chitosan nanoparticle aqueous solution containing silver or vancomycin nanoparticles as doped antibacterial additives was coated onto the pre-washed bio-matrix substrate for 1-6 hours in a carbonated solution at a pressure of 20-30 MPa and a temperature of 23-27 °C to form a coating.
Need to check novelty before this filing date? Find Prior Art